mycophenolate mofetil

Type: Keyphrase

Name: mycophenolate mofetil

First reported Jun 12 2013 - Updated Jun 12 2013 - 3 reports

Teva reports positive results in Laquinimod lupus trial

The trial found that treatment with Laquinimod provides an additive effect in improving renal function.Teva Pharmaceutical Industries Ltd.(NYSE: TEVA; TASE: TEVA) and Active Biotech (Nasdaq: OMX NORDIC: ACTI) today announced the results of a Phase IIa ... [Published Globes - Jun 12 2013]

Entities: Laquinimod, Teva Pharmaceutical Industries Ltd, Systemic Lupus Erythematosus, Lupus Nephritis

First reported Jun 07 2013 - Updated Jun 07 2013 - 1 reports

Engineering Human T Cells for Resistance to Methotrexate and Mycophenolate Mofetil as an In Vivo Cell Selection Strategy

by Mahesh Jonnalagadda, Christine E. Brown, Wen-Chung Chang, Julie R. Ostberg, Stephen J. Forman, Michael C. JensenGene transfer and drug selection systems that enforce ongoing transgene expression in vitro and in vivo which are compatible with human ... [Published Elites TV - Jun 07 2013]

Entities: In Vivo, mycophenolate mofetil, Methotrexate

First reported Jun 04 2013 - Updated Jun 04 2013 - 1 reports

May 31: Recent transplant news

Discarded human kidneys as a source of ECM scaffold for kidney regeneration technologiesNCBIIn the United States, more than 2600 kidneys are discarded annually, from the total number of kidneys procured for transplant. It has been hypothesized that this ... [Published American Society of Transplantation - Jun 04 2013]

Entities: Kidney, Inflammatory Bowel Disease, Patient, immunosuppressive, Tolerance

First reported May 22 2013 - Updated May 22 2013 - 1 reports

A Randomized, Open-Label Study of Sirolimus Versus Cyclosporine in Primary De Novo Renal Allograft Recipients

Background: Despite a decreased incidence of acute rejection and early renal allograft loss due to calcineurin inhibitors (CNIs) in transplant recipients, nephrotoxicity associated with long-term CNI use remains an important issue. This study evaluated ... [Published Transplantation - May 22 2013]

Entities: sirolimus, cyclosporine, de Novo, Kidney

First reported Apr 02 2013 - Updated Apr 02 2013 - 1 reports

Neuromyelitis optica in patients with coexisting human immunodeficiency virus infections

Two patients with known human immunodeficiency virus (HIV) infections and receiving antiretroviral treatment developed neuromyelitis optica (Devic’s disease). One patient tested positive for serum aquaporin-4 immunoglobulin G antibodies. Both patients ... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Apr 02 2013]

Entities: Neuromyelitis Optica, HIV/AIDS, infections, Patient

Quotes

The overall use of rituximab was estimated at 0.5-1.3% of all SLE patients, mostly in those with more severe and refractory disease, "which is of course also in keeping with the fact that this is an off-label therapy" says Ronald van Vollenhoven MD PhD, a professor in the Unit for Clinical Therapy Research in Inflammatory Diseases at the Karolinska University Hospital...

Off-Label Rituximab for Lupus in Europe: Used Seldom, But Widely [Published Consultant Live - Jun 16 2013]

"The favorable trends towards laquinimod treatment in the renal end-points, coupled with the safety and tolerability profile, provide a rationale for further Phase III clinical studies" said Principal Investigator Dr. David Jayne, Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge

TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS FROM PHASE IIa STUDY OF LAQUINIMOD IN ACTIVE LUPU ... [Published PipelineReview - Jun 12 2013]

"It is an important milestone, setting a 'book-end' case for the industry. It will serve to encourage patent settlements" Bernstein Research analyst Aaron Gal said in a note

Teva, Sun Pharma to pay $2.15 bln to settle Pfizer patent suit [Published Yahoo! UK and Ireland - Jun 12 2013]

Perrone C, et al "A two-year retrospective analysis of rituximab therapy in secondary-progressive MS" CMSC-ACTRIMS 2013; Abstract P28

Study Hints of Rituximab MS Benefit (CME/CE) [Published MedPage Today - Jun 03 2013]

More Content

sort by: Date \| Relevance
Azathioprine Not Linked to Flare Risk in Lupus ... [Published Consultant Live - 3 hours ago]
Risk Factors for BK Virus Infection in the Era ... [Published Transplantation - 10 hours ago]
Off-Label Rituximab for Lupus in Europe: Used S... [Published Consultant Live - Jun 16 2013]
TEVA AND ACTIVE BIOTECH REPORT POSITIVE RESULTS... [Published PipelineReview - Jun 12 2013]
Teva, Sun Pharma to pay $2.15 bln to settle Pfi... [Published Yahoo! UK and Ireland - Jun 12 2013]
Teva reports positive results in Laquinimod lup... [Published Globes - Jun 12 2013]
Teva, Active Biotech Announce Results Of Phase ... [Published RTTNews.com - Jun 12 2013]
Teva Pharma (TEVA), Active Biotech Update on La... [Published Street Insider - Jun 12 2013]
TEVA: Study Shows Combined Use of Laquinimod Im... [Published 4 Traders - Jun 12 2013]
Thymoglobulin and Its Use in Renal Transplantat... [Published Sexual Development - Jun 11 2013]
Engineering Human T Cells for Resistance to Met... [Published Elites TV - Jun 07 2013]
PML Reported in Patients Taking Psoriasis Compo... [Published Neurology Today - Jun 07 2013]
AIR Presents a True Diagnostic Challenge [Published Review of Ophthalmology - Jun 05 2013]
May 31: Recent transplant news [Published American Society of Transplantation - Jun 04 2013]
Study Hints of Rituximab MS Benefit (CME/CE) [Published MedPage Today - Jun 03 2013]
Amelioration of motor/sensory dysfunction and s... [Published 7thSpace - May 28 2013]
A Randomized, Open-Label Study of Sirolimus Ver... [Published Transplantation - May 22 2013]
Engineered anti-IL-23P19 antibodies [Published PharmCast - Apr 09 2013]
Neuromyelitis optica in patients with coexistin... [Published Multiple Sclerosis Journal RSS feed -- OnlineFi ... - Apr 02 2013]
New Paid Lupus Clinical Trial Now Enrolling at ... [Published PRWeb - Nov 27 2012]